← Retour à la une
États-Unis · Agences & temps réel · PR Newswire

Dechra acquires biotechnology company, Gallant Pet, Inc.

Publié par PR Newswire · États-Unis il y a 49 min
Dechra Acquires Gallant
Dechra Acquires Gallant · PR Newswire

Résumé détaillé

Expansion into regenerative medicine is a strategic move to broaden treatment possibilities, address unmet needs and shape the future of veterinary care BOSTON, Nov. 17, 2026…

Expansion into regenerative medicine is a strategic move to broaden treatment possibilities, address unmet needs and shape the future of veterinary care

BOSTON, Nov. 17, 2026 /PRNewswire/ -- Dechra, a global leader in veterinary specialty care, today completed its acquisition of Gallant Pet Inc (Gallant), a U.S.-based animal health biotechnology company pioneering off-the-shelf mesenchymal stromal cell (MSC) therapies for pets. Representing another milestone on Dechra's transformation journey, the expansion into regenerative medicine has the potential to broaden treatment options for complex conditions, address significant unmet needs and help shape the future of veterinary care through a new therapeutic platform.

These ready-to-use, MSC therapies are designed to work with the body's natural biological processes. By bringing this first-of-its-kind therapy into the Dechra portfolio, the company is advancing a new therapeutic platform designed to treat chronic and complex conditions in pets.

"This acquisition is a strategic investment in expanding what's possible in veterinary care," said Dr. Cathy Knupp, Chief Scientific Officer, Dechra. "By combining our specialty animal health expertise, global reach and established veterinary relationships with Gallant's scientific innovation and regenerative medicine platform, we're creating a strong foundation to bring new treatment options to veterinarians and their patients."

Designed to support multiple therapies across different conditions and species, Gallant's pipeline creates opportunities for continued innovation and development as well as a platform with the potential to establish regenerative medicine as a valued standard in veterinary practice.

"Gallant was built on a bold idea that we could make regenerative medicine accessible for all pets in need," said Dr. Linda Black, CEO of Gallant. "Dechra understood that vision from the start.

The first innovation from the pipeline is anticipated as early as 2027.

Dechra is a global…

Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur PR Newswire Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)

À lire aussi